BUZZ—First Tracks shares surge boosted by positive results from clinical trials of celiac disease medication

October 12 - ** Biotechnology company First Tracks Biotherapeutics (TRAX.O) shares surged 16.2% in pre-market trading to $37

** The company announced (link) that its drug ANB033 for the treatment of celiac disease has achieved positive preliminary results in a gluten challenge trial

** ANB033 is the company's experimental antibody drug for treating autoimmune and inflammatory diseases, including celiac disease

** Celiac disease is an autoimmune disease in which gluten intake damages the small intestine

** TRAX said that ANB033 effectively suppressed the worsening of symptoms during the 14-day gluten intake period

** Reports indicated that ANB033 was well tolerated, with no serious adverse events reported

** The initial data from cohort 2 of the ANB033 study in celiac disease is expected to be released in the first quarter of 2027, and the initial data for its study in eosinophilic esophagitis is expected in the third quarter of 2027

** Phase II clinical development of ANB033 in vitiligo and another indication is expected to begin in the first half of 2027

** Since its initial public offering (IPO) in April, TRAX's share price has nearly doubled

(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may be inaccurate or lack necessary context, Reuters makes no guarantees as to the accuracy of the translated text. The translations are provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss arising from the use of the automated translation.)